Full-Time

Principal Quality Operations Engineer

Updated on 9/3/2026

AtriCure

AtriCure

1,001-5,000 employees

Sells ablation devices for atrial fibrillation

No salary listed

United States

In Person

On-site in the United States; travel up to 15%.

Bachelor's

Category
Manufacturing Quality & Test (1)
Required Skills
Risk Management
Data Analysis

Get referred to AtriCure

See people who can refer or advise you

Requirements
  • Bachelor’s degree in engineering, or an equivalent combination of education, training, and experience.
  • Minimum of 10 years of experience in the Medical Device Manufacturing Experience, or Manufacturing production and process control experience within a regulated industry.
  • Experience with facility, utility, equipment, and/or process validation in a regulated manufacturing environment, preferably medical device manufacturing.
  • Working knowledge of production and process controls, ISO 13485, GMP requirements, quality system procedures, and applicable validation standards and practices.
  • Ability to develop and implement quality system programs, policies, procedures, technical documentation, validation master plans, and related controls.
  • Demonstrated ability to lead cross-functional teams, influence alignment, facilitate decisions, and resolve complex technical and quality issues.
  • Strong verbal, written, and presentation skills, including technical protocol and report development, stakeholder communication, and project status reporting.
  • Ability to read and interpret technical specifications, blueprints, drawings, and related facility or engineering documentation.
  • Strong problem-solving, troubleshooting, attention to detail, compliance orientation, and results-driven execution.
  • Proficiency with computer-based systems, data entry, and basic data analysis or statistical tools.
  • Ability to travel up to 15%.
Responsibilities
  • Lead the risk management program for critical facility and utility systems, including risk governance, escalation, timely investigation, and implementation of mitigations for identified risks, excursions, and quality issues.
  • Define quality documentation expectations for facility and utility systems, including user needs, requirements, drawings, specifications, risk documentation, validation evidence, process controls, and related records.
  • Establish quality strategies, Quality Plans, and validation master plans to guide large facility updates, utility changes, and critical system lifecycle management in alignment with AtriCure validation and quality system policies.
  • Lead strategic quality and facility implementation programs from initiation through completion, including priorities, deliverables, resource alignment, stakeholder engagement, risk-based decision-making, and executive-level status communication.
  • Advise cross-functional teams on facility change requests, including line moves, equipment moves, utility additions, and related changes that support production operations and require quality impact assessment.
  • Provide technical authority for qualification and validation strategies applied to critical facility, utility, equipment, monitoring, and data systems, including development, execution, review, and approval of IQ/OQ/PQ documentation and lifecycle activities.
  • Lead validation and data integrity practices for systems that capture critical facility and utility data, including dashboards, alert and action limits, trend monitoring, and escalation of conditions requiring investigation or corrective action.
  • Drive development and improvement of quality system procedures and program controls governing critical facility and utility systems and supporting Quality Operations programs.
  • Champion continuous improvement opportunities that increase efficiency, capacity, reliability, compliance, and operational readiness of critical facility and utility systems.
  • Serve as a senior quality and engineering resource for facilities management, equipment qualification, process validation, preventive maintenance, and calibration activities related to Quality Operations-owned equipment.
  • Influence Facilities, Quality Management, Operations, and other departments to assess system capacity, support company strategies, resolve complex issues, and maintain alignment with business and quality objectives.
  • Define and communicate metrics that assess the health, performance, capacity, and compliance status of critical facility and utility systems, including status updates to quality, operational, and leadership forums.
  • Represent Quality Operations during internal and external audits, including preparation, response, and follow-up activities related to critical facility and utility systems.
  • Mentor Quality Operations engineers, build technical capability across the team, and provide trusted partnership and guidance to key stakeholders.
  • Lead with expert knowledge of prescribed GMP, ISO, and GLP standards and ensure compliance with applicable domestic and international regulations, standards, and controls relevant to risk management, process validation, environmental monitoring, and related areas.
Desired Qualifications
  • Experience in medical device manufacturing, quality operations, or quality management, preferably supporting sterile medical devices.
  • Knowledge of cleanroom validation, contamination control, environmental monitoring, pest control, and facility-related safety practices.
  • Facility engineering, facility design, construction, or manufacturing infrastructure experience in a regulated environment.
  • Project management experience; PMP certification preferred.
  • Technical file or CAD drawing management experience.
  • FDA, ISO, or other regulatory audit experience.
  • ASQ Certified Quality Engineer and/or ASQ Certified Six Sigma Black Belt certification.

AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Chester, Pennsylvania

Founded

1994

Get referred to AtriCure

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On July 23, 2026, AtriCure raised 2026 revenue guidance to $602 million-$610 million.
  • Q2 2026 revenue hit $153.6 million, with adjusted EBITDA rising 78% to $27.3 million.
  • BoxX-NoAF reached 50% enrollment ahead of schedule, with data expected in 2027.

What critics are saying

  • Medtronic’s Affera Sphere-360 and Boston Scientific’s PFA systems attack AtriCure’s core surgery workflows.
  • BoxX-NoAF and LeAAPS still define upside; any trial failure erases expansion plans.
  • If PFA catheter adoption shifts surgeons away, AtriCure’s surgical ablation franchise shrinks permanently.

What makes AtriCure unique

  • AtriCure’s EnCompass and AtriClip platforms bundle surgical ablation, appendage exclusion, and training.
  • CryoSPHERE MAX halved freeze times and drove pain-management adoption in Q2 2026.
  • LeAAPS enrolled 6,573 patients, giving AtriCure the largest cardiac-surgery device trial.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Wellness Program

401(k) Company Match

Parental Leave

Pet Insurance

Employee Stock Purchase Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 12th, 2026
AtriCure targets $1B revenue by 2030 as pain management volumes jump 25%

AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.

Yahoo Finance
Jul 28th, 2026
AtriCure beats Q2 estimates with $153.6M revenue and 800% EPS surprise, raises full-year guidance

AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.

Yahoo Finance
Jul 24th, 2026
AtriCure reports $154M revenue, 13% growth and $9M net income in Q2 2026

AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.

Yahoo Finance
Jun 4th, 2026
AtriCure accelerates heart disease trial by 12 months, beats Q1 revenue by $2M

AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.

Yahoo Finance
May 12th, 2026
AtriCure targets 12–14% growth in 2026 with new devices and EnCompass platform expansion

AtriCure expects 12% to 14% revenue growth in 2026, driven by recent and upcoming product launches including cryoSPHERE MAX, cryoXT and new appendage-management devices. President and CEO Michael Carrel and CFO Angela Wirick discussed the outlook at a Bank of America fireside chat, following 15% revenue growth in 2025. The company's EnCompass ablation platform and AtriClip continue to show significant runway, with executives citing a large untapped cardiac-surgery market and strong surgeon adoption. A next-generation V-Clip appendage product is expected in 2027. AtriCure guided 2026 adjusted EBITDA at $80 million to $82 million whilst maintaining profitability improvements. The cryoXT device, targeting lower-extremity amputations, had a soft launch in late 2025 and is expected to contribute more meaningfully in the second half of 2026.